5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie

3. Nektar Therapeutics (NASDAQ: NKTR)

Maverick Capital’s Stake Value: $98,860,000
Percent of Maverick Capital’s 13F Portfolio: 0.92%
Number of Hedge Fund Holders: 21

Nektar Therapeutics (NASDAQ: NKTR) is a global biopharmaceutical company that develops therapies and treatments for autoimmune diseases, cancers, and chronic inflammatory disorders.

Maverick Capital holds over 5.76 million shares in Nektar Therapeutics (NASDAQ: NKTR) as of the second quarter. The shares are valued at over $98.8 million. In Q2 2021, the company posted revenue of 28.3 million, beating the consensus by $2.15 million. In June, Stifel upgraded Nektar Therapeutics (NASDAQ: NKTR) to ‘Buy’ with a $24 price target due to the company’s successful initial data on lung cancer treatment.

As of Q2 2021, 21 hedge funds have positions in Nektar Therapeutics (NASDAQ: NKTR), up from 18 in the previous quarter. The total value of these positions is $234.4 million.